Treatment of Inoperable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Malignant peripheral nerve sheath tumors (MPNSTs) that are inoperable or have spread to distant sites represent a particularly challenging clinical scenario. In this setting, the overall prognosis is generally poor, and systemic therapy becomes the central management consideration.

Clinical Scenario

This protocol applies to patients with inoperable MPNST — where surgical resection is not feasible — or with metastatic MPNST, where the disease has spread beyond the primary site. For inoperable or metastatic MPNST, the outcome is usually poor.

Treatment Approach

Subsequent-line systemic therapy options in this setting involve combination or single-agent chemotherapy regimens drawn from agents used in advanced soft tissue sarcoma.

The complete regimen — including specific agents, sequencing, and eligibility criteria — is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers16193266

For inoperable or metastatic MPNST, the outcome is usually poor.
Data are lacking on the MPNST-specific efficacy of further lines of systemic therapy commonly used in advanced STS (for instance, gemcitabine in combination with Docetaxel or dacarbazine and trabectedin), but objective response rates (ORR) are seen in around 10–15% of the cases.

View source ↗